MSH6: Definition



Print this article

MSH6 is a protein that helps cells fix DNA mistakes. It is one of four mismatch repair proteins that pathologists test for in many cancers. When a tumor has lost MSH6, it cannot repair some of these mistakes. Loss of MSH6 can point to an inherited condition called Lynch syndrome. It can also affect which treatments your doctors consider. MSH6 results need careful interpretation, because weak or patchy staining can have other causes.

This article explains what MSH6 does, how pathologists test for it, what retained, lost, and patchy MSH6 results mean, and what happens next.

What does MSH6 do?

MSH6 works like a spell-checker for DNA. Cells make small copying mistakes each time they divide. MSH6 helps find these mistakes so other proteins can fix them.

MSH6 works with another protein, MSH2. The pair spots the mistake. A second pair, MLH1 and PMS2, then helps repair it. These four proteins make up the mismatch repair system.

The MSH6 gene holds the instructions for making the MSH6 protein. It is a tumor suppressor gene. When both copies stop working, mistakes build up in the DNA and can lead to cancer.

How do pathologists test for MSH6?

Pathologists test for MSH6 using immunohistochemistry. This test uses an antibody that sticks to the MSH6 protein in a thin slice of tumor tissue. Cells that contain MSH6 show brown staining in their nuclei.

Laboratories almost always test MSH6 together with MLH1, PMS2, and MSH2. Together, the four stains make up the mismatch repair, or MMR, panel. Laboratories commonly run this panel on colorectal and endometrial cancers, as well as many others.

The pathologist compares the tumor cells with normal cells on the same slide. Immune cells and other normal cells should always stain. They act as a built-in check that the test worked.

What do MSH6 results mean?

Your report will usually describe MSH6 as retained or lost. Some reports also describe a patchy or reduced pattern:

  • Retained, intact, or preserved. The tumor cells contain MSH6. This is the normal result.
  • Lost, absent, or loss of expression. The tumor cells do not contain MSH6, while normal cells nearby do. The tumor is mismatch repair deficient, often written as dMMR.
  • Patchy, focal, weak, or reduced. Only some tumor cells stain, or the staining is faint. This pattern needs careful interpretation, described below.

When a tumor keeps all four MMR proteins, pathologists call it mismatch repair proficient (pMMR).

What do the different MSH6 loss patterns mean?

The meaning of MSH6 loss depends on which other MMR proteins are also missing. Pathologists look at the four results together:

  • Loss of MSH2 and MSH6. MSH6 needs MSH2 to stay stable. When MSH2 is missing, MSH6 is usually lost too. This pattern points to a problem with MSH2 or a nearby gene called EPCAM.
  • Loss of MSH6 alone. MSH2 is retained, but MSH6 is missing. This pattern points to a problem with the MSH6 gene itself. The cause may be an inherited change or a change limited to the tumor.
  • Loss of MLH1 and PMS2, with patchy MSH6. Some tumors that have lost MLH1 and PMS2 later damage MSH6 as well. This extra change happens only in the tumor. It does not usually mean an inherited MSH6 change.

Why might MSH6 staining look patchy or weak?

MSH6 staining can look patchy or weak for reasons other than an inherited change. Common causes include:

  • Treatment before surgery. Chemotherapy or radiation given before surgery can reduce MSH6 staining. In one study of treated colorectal cancers, 20 percent showed reduced MSH6. All of those tumors were stable on a separate DNA test called microsatellite instability (MSI) testing.
  • Changes limited to the tumor. As described above, tumors that have lost MLH1 and PMS2 may lose MSH6 in some areas.
  • Sample handling. Staining can look weaker at the edges of a small biopsy.

When MSH6 looks patchy after treatment, the pathologist may repeat the stain on the original biopsy taken before treatment. MSI testing can also help.

What happens if my tumor has lost MSH6?

Loss of MSH6 leads to two separate questions for your care team. One is about your family, and one is about treatment.

  • Genetic counseling and testing. Your doctor may refer you for genetic counseling. A blood or saliva test looks for an inherited change in MSH6 that causes Lynch syndrome. If the test finds one, your relatives can have testing for the same change.
  • Tumor sequencing. If genetic testing finds no inherited change, the laboratory may use next-generation sequencing to test the tumor. Two MSH6 changes in the tumor support a non-inherited cause.
  • Immunotherapy. Mismatch repair deficient tumors carry many DNA mistakes, which help the immune system recognize the cancer. In 2017, the FDA gave accelerated approval to pembrolizumab for advanced dMMR solid tumors that had grown after earlier treatment.

The FDA has also approved other immunotherapy drugs for specific dMMR cancers. One example is dostarlimab, which received FDA approval in 2023 for advanced dMMR endometrial cancer that has grown after platinum chemotherapy. Approvals differ between countries. Your oncologist can explain which options apply to your cancer and stage.

Questions to ask your doctor

  • Was MSH6 retained, lost, or patchy in my tumor?
  • Were the other mismatch repair proteins retained?
  • Did I have chemotherapy or radiation before the laboratory tested my tissue?
  • Should the laboratory repeat the stain on my original biopsy?
  • Was microsatellite instability (MSI) testing done?
  • Should I have genetic counseling and germline testing?
  • Do my relatives need testing?
  • Does this result change my treatment options, including immunotherapy?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?